These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 39218648)
1. Optimized Antifungal Therapy for Chronic Pulmonary Aspergillosis. Yagi Y; Yamagishi Y; Hamada Y Med Mycol J; 2024; 65(3):59-65. PubMed ID: 39218648 [TBL] [Abstract][Full Text] [Related]
2. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent. Rybak JM; Marx KR; Nishimoto AT; Rogers PD Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Livermore J; Hope W Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880 [TBL] [Abstract][Full Text] [Related]
4. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Guinea J; Bouza E Future Microbiol; 2008 Dec; 3(6):603-15. PubMed ID: 19072177 [TBL] [Abstract][Full Text] [Related]
5. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Miceli MH; Kauffman CA Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012 [TBL] [Abstract][Full Text] [Related]
6. [Expert consensus on the diagnosis and treatment of pulmonary aspergillosis in patients with chronic obstructive pulmonary disease]. Chinese Thoracic Society of Chinese Medical Association Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jul; 47(7):604-622. PubMed ID: 38955746 [TBL] [Abstract][Full Text] [Related]
12. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179 [TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi. Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396 [TBL] [Abstract][Full Text] [Related]
14. Isavuconazole: A New Option for the Management of Invasive Fungal Infections. Pettit NN; Carver PL Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222 [TBL] [Abstract][Full Text] [Related]
15. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity. Ledoux MP; Denis J; Nivoix Y; Herbrecht R J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442 [TBL] [Abstract][Full Text] [Related]
16. Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis. Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA Mycoses; 2021 Apr; 64(4):445-456. PubMed ID: 33355949 [TBL] [Abstract][Full Text] [Related]
17. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Thompson GR; Wiederhold NP Mycopathologia; 2010 Nov; 170(5):291-313. PubMed ID: 20524153 [TBL] [Abstract][Full Text] [Related]
18. Isavuconazole: Case Report and Pharmacokinetic Considerations. Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443 [TBL] [Abstract][Full Text] [Related]
19. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607 [TBL] [Abstract][Full Text] [Related]
20. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]